Global Anticoagulant Reversal Drugs Market Overview
The key driver impacting the anticoagulant reversal drugs market is the growing prevalence of bleeding disorders and the rise in the incidence of indications for anticoagulant therapy. For instance, As per the National Institutes of Health, bleeding disorders allegedly affect 1 in 1,000 men and women worldwide. Haemophilia A and B and von Willebrand disease make up the most widespread types of bleeding disorders. As per the National Hemophilia Foundation (NHF) data, around 30,000 to 33,000 people have hemophilia, and 60% have serious hemophilia. The Center for disease control and prevention (CDC) reports estimations every year. Around 400 babies born with hemophilia A in the U.S. Von Willebrand disease are considered the most common bleeding disorders that affected 1 in every 100 people. Moreover, the growing approval and launch of new reversal agents for anticoagulants is estimated to be a significant factor contributing to market growth.
According to Value Market Research, the global anticoagulant reversal drugs market size was valued at around USD 700 million in 2020 and is projected to grow at a CAGR of about 14% during the forecast period of 2021 to 2027.
The rise in the global prevalence of multiple cardiovascular indications such as atrial fibrillation, rise in intracranial and gastrointestinal hemorrhages with the growing geriatric population is estimated to augment anticoagulant reversal drugs demand in the forecast period. For instance, Cardiovascular diseases (CVDs) are the number 1 cause of death globally, taking an estimated 17.9 million lives each year. CVDs refer to the group of heart and blood vessel disorders and include cerebrovascular disease, rheumatic heart disease, coronary heart disease, and other conditions. However, the high cost of reversal therapies may hamper the global anticoagulant reversal drugs market in the long run. The current industry trends, such as the rise in governments' financial aid encouraging the creation of effective therapeutics, are expected to provide market players with new market opportunities.
The anticoagulant reversal drugs market is vast, with many local and global players. The key leaders follow different strategies to advance their market position, such as contracts, amalgamation, extending product portfolio, expansions, acquisitions, and product upgrades to raise their market share across the globe. The major players in the report are Portola Pharmaceuticals, CSL Behring, Boehringer Ingelheim, Octapharma AG, AMAG Pharmaceuticals, Inc., Dr. Reddy's Laboratories, Pfizer, Inc., Fresenius Kabi AG, Bausch Health Companies Inc., Octapharma AG, SGPharma Pvt. Ltd., and Alps Pharmaceutical Ind. Co., Ltd.
In this research report, the anticoagulant reversal drugs market is segmented by product type, distribution channel, and region.
Analysis by Product Type:
By Product type, the report is categorized into prothrombin complex concentrates, phytonadione, andexanet alfa, idarucizumab, protamine, and others. The idarucizumab segment dominates the product type segment with over 35% share in 2020. It is due to the high revenue generation by idarucizumab in significant geographies. Moreover, the growing usage of idarucizumab in patients treated with dabigatran when there is a requirement of reversal of the anticoagulant effects is required for urgent procedures or uncontrolled incidents or life-threatening bleeding driving demand for idarucizumab in the forecast period.
Analysis by Distribution Channel:
By distribution channel, the report is categorized into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment dominates the distribution channel segment with over 50% share in 2020. It is due to the hospitals being the primary centers for diagnosing and treating various types of bleeding disorders. Moreover, uncontrolled bleeding during emergency conditions contributes to the high market demand from distribution channels in the forecast period.
Analysis by Region:
In the regional outlook of the global anticoagulant reversal drugs market, the North America region dominates with a 40% market share during the forecast period. It is due to the high healthcare expenditure and favorable healthcare reimbursement policies for costly drugs throughout the region. The increasing awareness and rising incidence of bleeding disorders in the region add growth to the region. Moreover, the easy availability of these reversal drugs during emergency conditions contributes to the development of the anticoagulant reversal drugs market in North America.
Market Segmentation covered in the Report:
By Product Type
- Prothrombin Complex Concentrates
- Phytonadione
- Andexanet Alfa
- Idarucizumab
- Protamine
- Others
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.